Roche Holding AG
corporate_fare Company Profile
Roche Holding AG (OTC:RHHBY) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 4 items for RHHBY at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-01, rated 7/10. Across its 4 most recent items scored 7 or higher, the top rating is 8/10, with 2 rated 8 or above.
Recent high-impact activity:
- Vabysmo Real-World Data Show Durable Vision Gains Across Retinal Diseases
- Roche's Giredestrant Combo Nearly Doubles PFS in Advanced Breast Cancer; FDA Accepts NDA
- FDA Accepts Roche's Fenebrutinib Filing for Both Relapsing and Primary Progressive MS
- Roche Wins European Approval for Susvimo in Neovascular AMD
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 2,411,872 shares in RHHBY as of the September 15, 2026 settlement, a 19.6% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On October 2, 2026, 27.6% of RHHBY volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.